A Multicenter, Open-label, Single-arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Neonates With Repeated Electroencephalographic Seizures
Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 13 Aug 2018
At a glance
- Drugs Brivaracetam (Primary) ; Brivaracetam (Primary)
- Indications Neonatal seizures
- Focus Pharmacokinetics
- Acronyms PETITE
- Sponsors UCB Biopharma
- 01 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Aug 2018.
- 01 Jul 2018 Planned End Date changed from 20 Nov 2020 to 1 Jan 2021.
- 01 Jul 2018 Planned primary completion date changed from 1 Oct 2020 to 1 Dec 2020.